Most Problematic Leukemia Drugs Recalled (China)
This article was originally published in PharmAsia News
Executive Summary
Chinese officials announced they have successfully recalled the majority of two-types of leukemia drugs. Methotrexate and cytarabin hydrochloride, both manufactured by Shanghai Hualian Pharmaceutical, Co. were recalled by Chinese health authorities as of Sept. 5 after reports of unusual side-effects. The Chinese Ministry of Health and the State Food and Drug Administration have since been working with Shanghai Hualian to remove the two drugs from the market and trace the cause of the side-effects. As of Sept. 14, officials announced they have found the source of the mysterious symptoms, which included trouble walking and urine retention. According to reports, the side-effects were the result of the accidental addition of vincristine sulfate, another anti-cancer treatment, into several batches of the leukemia treatments. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.